Verona Pharma's Ensifentrine was accepted for NDA Review by FDA for chronic obstructive pulmonary disease (COPD) maintenance treatment. COPD is used to describe chronic lung diseases, encompassing emphysema, and chronic bronchitis. Phase 3 ENHANCE trials demonstrated Ensifentrine's efficacy and safety, showing significant improvements in lung function, symptom endpoints, and reducing the rate and risk of COPD exacerbations. Ensifentrine offers a novel mechanism of action. It is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4); it is also an activator of the cystic fibrosis transmembrane conductance regulator (CFTR).
検索 
+86 21 5895 0110 
